Identify the PIK3CA mutations that make a difference in breast cancer

Contact an expert

Empower your oncologists with results they can trust 

The therascreen PIK3CA RGQ PCR Kit is the first FDA-approved companion diagnostic (CDx) test to identify patients with advanced breast cancer for whom treatment with the ∝-selective PI3K-inhibitor PIQRAY (alpelisib) may be appropriate.

Discover the test

Reliably detect actionable mutations

The therascreen PIK3CA RGQ PCR Kit is a unique molecular test, based on the detection of specific PIK3CA mutations in tumor DNA isolated from either FFPE tumor tissue or plasma samples. The kit detects 11 mutations in exons 7, 9, and 20 of the PIK3CA gene (exon 7: C420R; exon 9: E542K; E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and exon 20: H1047L, H1047R, H1047Y).

Learn more about the test.

Find a lab offering this new PIK3CA test.

The tools you need to ensure patients receive the best individualized care

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Photo taken prior to COVID-19

Browse our products!